Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic or prophylactic agent for cachexia

A cachexia and preventive agent technology, applied in the direction of blood diseases, extracellular fluid diseases, medical preparations containing active ingredients, etc., can solve the problems of no disclosure and achieve the effect of improving weight loss

Active Publication Date: 2013-09-25
TORAY IND INC
View PDF23 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are no publications regarding the therapeutic or preventive effects of dyscrasias

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic or prophylactic agent for cachexia
  • Therapeutic or prophylactic agent for cachexia
  • Therapeutic or prophylactic agent for cachexia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0083] (Example 1) (-)-17-(cyclopropylmethyl)-3,14β-dihydroxy-4,5α-epoxy-6β-[N-methyl-trans- Life-prolonging effect and weight-loss inhibiting effect of 3-(3-furyl)acrylamide]morphinan hydrochloride (Compound 1)

[0084] [chemical 6]

[0085]

[0086] Using the dyscrasia model animal of B16 / F10 melanoma cell-C57BL / 6 mouse transplantation line, the therapeutic effect of compound 1 on dyscrasia was studied. As comparative controls, morphine and CI-977 were used. Morphine is an analgesic widely used for the treatment of cancer pain, and it is a compound having a morphinan skeleton similar to the compound of the present invention. On the other hand, CI-977 is an opioid κ receptor agonistic compound like the compound of the present invention (Br. J. Pharmacol., 1990, Vol. 101, p. 183-189).

[0087] C57BL / 6 mice transplanted with B16 / F10 melanoma cells developed dyscrasia symptoms such as weight loss and reduced exercise, along with tumor growth. The effects of various compou...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The purpose of the present invention is to provide a novel drug useful as a therapeutic or prophylactic agent for cachexia which is a systemic syndrome involving, as the main symptoms, a remarkable body weight loss, anemia, edema, anorexia, general prostration, a feeling of weariness and so on in chronic diseases such as malignant tumor, tuberculosis, diabetes, blood diseases, endocrine diseases, infections, acquired immune deficiency syndrome, etc. The present invention provides a therapeutic or prophylactic agent for cachexia comprising, as the active ingredient, a compound having a specific morphinan skeleton, a typical example of which is a compound having a structure represented by chemical formula (1), or a pharmacologically acceptable acid addition salt thereof.

Description

technical field [0001] The present invention relates to containing the morphinan skeleton ( ) compounds or their pharmacologically acceptable acid addition salts as active ingredients for dyscrasias ( ) therapeutic or prophylactic agent. Background technique [0002] Cachexia, also known as cachexia, is characterized by significant weight loss, anemia, edema, and loss of appetite in chronic diseases such as malignant tumors, tuberculosis, diabetes, blood diseases, endocrine diseases, infectious diseases, and acquired immunodeficiency syndrome. Systemic syndromes with main symptoms such as general weakness and fatigue (Non-Patent Documents 1 and 2). [0003] Among these dyscrasias, in particular, cancer cachexia, which is caused by malignant tumors, is often recognized and is said to account for about 20% of the deaths from malignant tumors (Non-Patent Document 3). In cancer cachexia, if the cachexia worsens, the patient's physical strength is significantly weakened, and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/485A61P3/00A61P35/00
CPCA61K31/485A61P1/14A61P3/00A61P7/00A61P7/06A61P7/10A61P35/00
Inventor 铃木知比古吉泽良隆平形美树人
Owner TORAY IND INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com